Sign up USA
Proactive Investors - Run By Investors For Investors

Maxim Group initiates SCYNEXIS with Buy rating and US$6 price target on promise of its antifungal drug SCY-078

SCY-078 is a sought-after antifungal drug that works against both yeasts and molds
Scientist in a lab
The treatment shows promise in an era of drug-resistant infections

Jason McCarthy of Maxim Group is kicking off coverage of the biotech company SCYNEXIS Inc (NASDAQ:SCYX) with a Buy rating and a US$6 price target on the strength of its novel antifungal drug SCY-078.

At a time when infections are rising, SCY-078 is a sought-after antifungal drug that works against both yeasts and molds, including strains resistant to drugs, that cause mucosal and invasive fungal infections.

“We see opportunity for Scynexis investors as its current valuation is only US$80m and SCY-078 is a novel antifungal in an era of rising infections, high mortality rates and resistance to available antifungals,” wrote Maxim’s McCarthy in a note to investors.

SCY-078 has all the desirable features of an antifungal that could translate into high adoption if approved, according to McCarthy. It is in clinical development for the treatment of a range of serious fungal infections, including vulvovaginal candidiasis (VVC), invasive candidiasis (IC), invasive aspergillosis (IA) and refractory invasive fungal infections.

In recent pre-clinical studies, SCY-078 was given to Wistar rats and Dutch-belted rabbits to assess its impact on embryo and fetal development.

“These studies provide evidence that SCY-078 does not exhibit developmental or reproductive toxicity when administered to animals before and/or during gestation,” said David Angulo, chief medical officer of SCYNEXIS. “The treatment of fungal infections during pregnancy has long been challenging due to the well-known developmental toxicities associated with existing antifungal treatments."

A Phase 2b study is also being conducted to assess the safety and tolerability of SCY-078 taken orally compared to a rival anti-fungal drug fluconazole by female patients with moderate to severe vaginal yeast infections. Data is expected from the trial in the third quarter of this year.

“In this infectious diseases space, an antifungal with broad spectrum activity that’s safe and available both orally and intravenously is likely to be widely adopted in our view,” concludes Maxim’s McCarthy.

SCYNEXIS stock was flat at US$1.70 in late morning trade.

Contact Ellen Kelleher: [email protected]

View full SCYX profile View Profile

SCYNEXIS, Inc. Timeline

Related Articles

laboratory
April 12 2018
Mission is to make stem cell treatments accessible and affordable to as many people as possible
1511901712_biotech_517925923.jpg
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
picture of addict
November 15 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use